Diagnostic Performance of PET or PET/CT with Different Radiotracers in Patients with Suspicious Lung Cancer or Pleural Tumours according to Published Meta-Analyses.

Details

Ressource 1Download: 32405280_BIB_D9FEC195D4E6.pdf (692.45 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_D9FEC195D4E6
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Diagnostic Performance of PET or PET/CT with Different Radiotracers in Patients with Suspicious Lung Cancer or Pleural Tumours according to Published Meta-Analyses.
Journal
Contrast media & molecular imaging
Author(s)
Lococo F., Muoio B., Chiappetta M., Nachira D., Petracca Ciavarella L., Margaritora S., Treglia G.
ISSN
1555-4317 (Electronic)
ISSN-L
1555-4309
Publication state
Published
Issued date
2020
Peer-reviewed
Oui
Volume
2020
Pages
5282698
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Several meta-analyses have reported data about the diagnostic performance of positron emission tomography or positron emission tomography/computed tomography (PET or PET/CT) with different radiotracers in patients with suspicious lung cancer (LC) or pleural tumours (PT). This review article aims at providing an overview on the recent evidence-based data in this setting.
A comprehensive literature search of meta-analyses published in PubMed/MEDLINE and Cochrane Library database from January 2010 through March 2020 about the diagnostic performance of PET or PET/CT with different radiotracers in patients with suspicious LC or PT was performed. This combination of keywords was used: (A) "PET" OR "positron emission tomography" AND (B) "lung" OR "pulmonary" OR "pleur <sup>∗</sup> " AND (C) meta-analysis. Only meta-analyses on PET or PET/CT in patients with suspicious LC or PT were selected.
We have summarized the diagnostic performance of PET or PET/CT with fluorine-18 fluorodeoxyglucose ( <sup>18</sup> F-FDG) and other radiotracers taking into account 17 meta-analyses. Evidence-based data demonstrated a good diagnostic performance of <sup>18</sup> F-FDG PET or PET/CT for the characterization of solitary pulmonary nodules (SPNs) or pleural lesions with overall higher sensitivity than specificity. Evidence-based data do not support the routine use of dual time point (DTP) <sup>18</sup> F-FDG PET/CT or fluorine-18 fluorothymidine ( <sup>18</sup> F-FLT) PET/CT in the differential diagnosis of SPNs. Even if <sup>18</sup> F-FDG PET/CT has high sensitivity and specificity as a selective screening modality for LC, its role in this setting remains unknown.
Evidence-based data about the diagnostic performance of PET/CT with different radiotracers for suspicious LC or PT are increasing, with good diagnostic performance of <sup>18</sup> F-FDG PET/CT. More prospective multicenter studies and cost-effectiveness analyses are warranted.
Pubmed
Web of science
Open Access
Yes
Create date
14/06/2020 20:42
Last modification date
23/11/2022 7:15
Usage data